Lentivirus Stable Cell Line Generation

Reference the resources below for more information about the product/service or contact us today to learn more.
Catalog # :
  • Description
  • Related Products

A comprehensive custom Lentiviral-based Stable Cell Line Generation Service for genetically engineering sensitive cells, primary cells, stem cells and terminally differentiated cells. Lentivirus-based stable cell line generation offers a cost-effective and efficient alternative for generating stable cell line models for gene overexpression, inducible gene expression, gene knockout and gene knockdown.

  • Broad tropism lentiviruses to target most mammalian cell types
  • Non-integrating lentiviruses for CRISPR-lenti gene knockout
  • Choice of selection markers: antibiotic resistance or GFP
  • 3rd generation lentiviral systems for the highest biosafety standards
  • Gene editing confirmed by NGS or RT-PCR

Cell Line Modifications:

  • Knock-in Cell Line Generation: We offer 3rd generation lentiviral system for stable gene knock-in into multiple cell types from most mammalian species.
  • CRISPR Knockout Cell Line Generation: We offer non-integrating lentiviruses (IDLVs) for CRISPR-lenti gene knockout or knock down modifications in hard-to-transfect cell lines.

Workflow includes:

  • Cell line validation
  • Generation of lentivirus; CRISPR vector construction and lentivirus packaging (if needed)
  • Reagent validation
  • Lentivirus transduction
  • Clone screening and confirmation
  • Cell expansion and cryopreservation

Service Specifications:

Customer should provide:

  • Frozen cells: 2 vials of 10^6 cells/ vial OR live cells: 2 x T25 flasks at 90% confluency
  • Detailed information regarding target gene and gene modification


  • Two vials of 1-2 clones or two vials of pooled clone.
  • Optional: negative control non-target gRNA-virus available
  • Milestone update/report; final report with detailed description of each procedure, including targeting vector design, construction and validation, transfection condition, genotyping strategy, and results.

Timeline: 3-6 months


  • Drug screening
  • Functional assays
  • Membrane protein screening
  • Long-term expression studies
  • Antibody immunization boosting
  • Gene therapy research